<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Parenteral empiric antibiotics for inpatient treatment of pediatric community-acquired pneumonia&lt;sup&gt;[1,2]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Parenteral empiric antibiotics for inpatient treatment of pediatric community-acquired pneumonia<sup>[1,2]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Parenteral empiric antibiotics for inpatient treatment of pediatric community-acquired pneumonia<sup>[1,2]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Age group and suspected pathogens</td> <td class="subtitle1">Suggested parenteral empiric agent(s)</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="3">1 to 6 months</td> </tr> <tr> <td class="indent1">Bacterial (not <em>Chlamydia trachomatis</em> or <em>Staphylococcus aureus</em>)</td> <td>One of the following: <ul class="decimal_heading"> <li>Ceftriaxone</li> <li>Cefotaxime</li> </ul> </td> <td> <ul> <li><strong>If CA-MRSA is suspected,</strong> ADD one of the following: <ul> <li>Vancomycin or clindamycin</li> <li>Ceftaroline* (alternative)</li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1"><em>C. trachomatis</em></td> <td>Azithromycin</td> <td> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">≥6 months</td> </tr> <tr> <td class="indent1">Uncomplicated bacterial (not <em>Mycoplasma pneumoniae</em>, <em>Chlamydia pneumoniae</em>, or <em>S. aureus</em>)</td> <td>One of the following: <ul class="decimal_heading"> <li>Ampicillin or penicillin G (preferred)</li> <li>Cefotaxime</li> <li>Ceftriaxone</li> </ul> </td> <td> <ul> <li>Cefotaxime and ceftriaxone are reserved for: <ul> <li>Children with incomplete Hib or <em>Streptococcus pneumoniae</em> immunizations, or</li> <li>Communities with substantial prevalence of penicillin-resistant <em>S. pneumoniae</em> (eg, ≥25%)</li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1"><em>M. pneumoniae</em> or <em>C. pneumoniae</em></td> <td>One of the following: <ul class="decimal_heading"> <li>Azithromycin</li> <li>Erythromycin</li> <li>Levofloxacin</li> </ul> </td> <td> </td> </tr> <tr> <td class="subtitle1">Clinical syndrome (any age)</td> <td class="subtitle1">Suggested empiric parenteral agent(s)</td> <td class="subtitle1">Comments</td> </tr> <tr> <td>Severe pneumonia</td> <td>Combination therapy with one of the following: <ul class="decimal_heading"> <li>Ceftriaxone</li> <li>Cefotaxime</li> </ul> <strong>PLUS</strong> one of the following: <ul class="decimal_heading"> <li>Azithromycin</li> <li>Erythromycin</li> <li>Doxycycline</li> </ul> </td> <td> <ul> <li>Children with severe infection may benefit from broad-spectrum therapy that addresses both typical and atypical pathogens</li> <li><strong>If <em>S. aureus</em> is a consideration, either</strong>: <ul> <li>ADD vancomycin or clindamycin, OR</li> <li>Provide therapy with ceftaroline* PLUS azithromycin</li> </ul> </li> </ul> </td> </tr> <tr> <td>Severe pneumonia requiring ICU admission</td> <td>Combination therapy with: <ul class="decimal_heading"> <li>Vancomycin</li> </ul> <strong>PLUS</strong> one of the following: <ul class="decimal_heading"> <li>Ceftriaxone</li> <li>Cefotaxime</li> </ul> <strong>PLUS</strong>: <ul class="decimal_heading"> <li>Azithromycin</li> </ul> <strong>PLUS</strong>: <ul class="decimal_heading"> <li>Antiviral treatment for influenza if the child is hospitalized during influenza season</li> </ul> </td> <td> <ul> <li><strong>If <em>S. aureus</em> is likely</strong>: <ul> <li>ADD nafcillin<sup>¶</sup>, OR</li> <li>SUBSTITUTE linezolid for vancomycin and nafcillin, OR</li> <li>Use ceftaroline* PLUS azithromycin PLUS antiviral treatment for influenza if the child is hospitalized during influenza season</li> </ul> </li> </ul> </td> </tr> <tr> <td>Complicated pneumonia (eg, effusion/empyema, necrotizing process, abscess<sup>Δ</sup>)</td> <td>Combination therapy with one of the following: <ul class="decimal_heading"> <li>Ceftriaxone</li> <li>Cefotaxime</li> </ul> <strong>PLUS</strong>: <ul class="decimal_heading"> <li>Clindamycin if <em>S. aureus</em> or anaerobic infection is a consideration</li> </ul> </td> <td> <ul> <li>Potential pathogens include <em>S. pneumonia</em>e, <em>S. aureus</em>, and <em>Streptococcus pyogenes</em></li> <li>Vancomycin is an alternative to clindamycin for children with allergy to clindamycin or high prevalence of clindamycin resistance in the community<sup>◊</sup></li> <li>Monotherapy with ceftaroline is an alternative if <em>S. aureus</em> is a consideration</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is meant for use with UpToDate content on the treatment of CAP in children. Refer to related UpToDate content for details regarding complete Hib and <em>S. pneumoniae</em> immunization, criteria for severe pneumonia, and pneumonia requiring ICU admission. Consultation with a specialist in infectious diseases for children is suggested for children with severe hypersensitivity to beta-lactam antibiotics (eg, penicillins and cephalosporins).</div><div class="graphic_footnotes"><p>CA-MRSA: community-associated methicillin-resistant <em>S. aureus</em>; Hib: <em>Haemophilus influenzae</em> type b; ICU: intensive care unit; CAP: community-acquired pneumonia; MSSA: methicillin-susceptible <em>S. aureus</em>; MRSA: methicillin-resistant <em>S. aureus</em>.</p>
<p>* Ceftaroline is a fifth-generation cephalosporin. It is available in the United States for the treatment of pediatric CAP due to <em>S. pneumoniae</em>, MSSA, and <em>H. influenzae</em> in children ≥2 months of age. Although ceftaroline has in vitro activity against MRSA, experience in children with documented MRSA CAP is limited.</p>
<p>¶ Nafcillin is added if <em>S. aureus</em> is likely because MSSA is more rapidly killed by nafcillin than by vancomycin.</p>
<p>Δ Ampicillin-sulbactam alone may be effective if lung abscess is thought to be secondary to aspiration.</p>
◊ The threshold prevalence of clindamycin-resistant MRSA (constitutive plus inducible) for choosing vancomycin varies from center to center, usually ranging from 10 to 25%, in an effort to balance the benefit of definitive therapy for the patient with the risk of increasing vancomycin resistance in the community. Additional considerations in the decision to choose vancomycin include the prevalence of MRSA in the community, the severity of illness, and the turn-around time for susceptibilities.</div><div class="graphic_reference">Data from:
<ol>
<li>McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429.</li>
<li>Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.</li>
</ol></div><div id="graphicVersion">Graphic 56260 Version 34.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
